Dr. Sergio Schwartzman is the Franchellie M. Cadwell Associate Professor of Clinical Medicine at Weill Cornell Medical College and an Associate Attending Physician at NewYork-Presbyterian Hospital and Hospital for Special Surgery. Dr. Schwartzman earned his medical degree at Mount Sinai School of Medicine in New York City. He completed his internship and residency in internal medicine at Long Island Jewish Medical Center in New Hyde Park, New York. His fellowship was conducted in the Department of Rheumatic Diseases at New York Hospital and Hospital for Special Surgery.
He is a member of the American College of Rheumatology (ACR), the Association for Research in Vision and Ophthalmology (ARVO), the Spondyloarthritis Research and Treatment Network (SPARTAN), the American Uveitis Society (AUS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Dr. Schwartzman is the recipient of The Fellows Award presented by the Northeast Regional American Rheumatism Association and The Franchellie M. Cadwell Chair.
He has served as an ad hoc journal reviewer for: Arthritis & Rheumatism, Emerging Infectious Diseases, Journal of Rheumatology, HSS Journal, Arthritis Care and Research, Seminars in Arthritis and Rheumatism and Arthritis Research & Therapy. He has been on the editorial advisory board for: Medscape Rheumatology, WebMD Rheumatology and Up to Date. He is also on the National Psoriasis Foundation Board and the Scientific Advisory Board of Crescendo Biosciences.
His current research interests and expertise are in: psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, rheumatoid arthritis and autoimmune diseases of the eye, including uveitis, vasculitis, scleritis and autoimmune orbital inflammatory disease.
Associate Attending Physician, Hospital for Special Surgery
Associate Professor, Weill Cornell Medical College
Autoimmune Eye Disorders
Castle Connolly Top Doctors in New York Metro Area, 2003-2019
New York Magazine Top Doctors, 2006, 2011, 2012, 2015
Colleck Lupus Fund
Phi Beta Kappa
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Schwartzman as of June 04, 2019.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.
Internal Medicine, 1985
Schwartzman, S., Fleischmann, R., & Morgan, G. J., Jr. (2004). Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther, 6 Suppl 2, S3-S11. doi: 10.1186/ar1013
Schwartzman, S., & Morgan, G. J., Jr. (2004). Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther, 6 Suppl 2, S19-23. doi: 10.1186/ar996.
Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. (2009). A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol, 61(1 Suppl 1), S1-S46. doi: 10.1016/j.jaad.2009.03.017.
Taylor, P., Manger, B., Alvaro-Gracia, J., Johnstone, R., Gomez-Reino, J., Eberhardt, E., Wolfe, F., Schwartzman, S., Furfaro, N., Kavanaugh, A. (2010). Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res, 38(4), 1213-1224.
Strober, B. E., Clay Cather, J., Cohen, D., Crowley, J. J., Gordon, K. B., Gottlieb, A. B., Kavanaugh, A. F., Korman, N. J., Krueger, G. G., Leonardi, C. L., Schwartzman, S., Sobell, J. M., Solomon, G. E.Young, M. (2012). A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb), 2(1), 1. doi: 10.1007/s13555-012-0001-y.
Schwartzman, S., Schwartzman, M. (2013). Whipple's disease. Rheum Dis Clin North Am, 39(2), 313-321. doi: 10.1016/j.rdc.2013.03.005.
Schwartzman, S., Schwartzman, M. (2014). The Use of Biologic Therapies in Uveitis. Clin Rev Allergy Immunol. doi: 10.1007/s12016-014-8455-6.
Ogdie A, Schwartzman S, Eder L, Maharaj AB, Zisman D, Raychaudhuri SP, Reddy SM, Husni E. (2014). Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol, 41(11), 2315-2322. doi: 10.3899/jrheum.140882.
Ogdie A, Schwartzman S, Husni E.(2015) Recognizing and Managing Comorbidites in Psoriatic Arthritis. Curr Opin Rheumatol. 2015 Mar;27(2):118-26.
Coates, L. C., Kavanaugh, A., Mease, P. J., Soriano, E. R., Laura Acosta-Felquer, M., Armstrong, A. W., Bautista-Molano, W., Boehncke, W. H., Campbell, W., Cauli, A., Espinoza, L. R., FitzGerald, O., Gladman, D. D.,Gottlieb, A., Helliwell, P. S., Husni, M. E., Love, T. J., Lubrano, E., McHugh, N., Nash, P., Ogdie, A., Orbai, A. M.,Parkinson, A., O'Sullivan, D., Rosen, C. F., Schwartzman, S., Siegel, E. L., Toloza, S., Tuong, W., Ritchlin, C. T.. (2016). "Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis." Arthritis Rheumatol 68(5): 1060-1071.
Fleischmann R, Mease PJ, Schwartzman S, Hwang L, Soma K, CA Connell, Takiya L, Bananis E. Effects of methotrexate dose on the efficacy of tofacitinib treatment outcomes from a Phase 3 clinical trial of patients with rheumatoid arthritis. Clin Rheumatol (2016). doi:10.1007/s10067-016-3436-1.
Viladomiu, M, Kivolowitz, C, Abdulhamid, A, Victorio, D, Castellanos, JG, Dogan, B, Simpson, K, Sczesnak, A, Wu, HJ, Chai, C, Diehl, G Ajami, N, Zhou, XK, Abramowitz, M, Jacob, V, Bosworth, B, Steinlauf, A, Schwartzman, S, Mandl, LA, Scherl, EJ, Longman, RS. Functional characterization of IgA-targeted E. coli in Crohn’s Disease-associated Spondyloarthritis Links Mucosal and Systemic Immunity. Sci Transl Med. 2017 Feb 8;9(376).
For more publications, please see the PubMed listing.